Загрузка...
Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
BACKGROUND: Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellula...
Сохранить в:
| Опубликовано в: : | BMC Gastroenterol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7166314/ https://ncbi.nlm.nih.gov/pubmed/32305059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-020-01236-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|